AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2010

Nov 3, 2010

30291_dirs_2010-11-03_d3c6a969-93ca-4311-aaff-d2c89b914330.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2010-11-01

Reporting Person: Cox John (EVP Pharmaceutical Oper & Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-01	Common Stock	F	360	$62.55	Disposed	17894.0411	Direct
2010-11-02	Common Stock	S	765	$63.0426	Disposed	17129.0411	Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: This represents the weighted average price for shares sold at a range between $62.96 (low) and $63.32 (high).

F3: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.